AI Designs Superior CAR T-Cell Binders for Cancer

Researchers at Memorial Sloan Kettering (MSK) have used generative AI to design new protein binders for CAR T-cell therapy ^[1]. These AI-generated binders target BCMA, a protein found in multiple myeloma cells ^[1][2]. In mouse models, these de novo proteins significantly outperformed existing FDA-approved binders ^[1][2].

The AI system creates proteins that do not exist in nature ^[1]. This breakthrough could expand treatment options for patients who do not respond to traditional immunotherapy ^[1][3]. Experts suggest this approach may accelerate the development of personalized cancer treatments ^[2].